Medicinal Chemistry Bioorganic & Medicinal Chemistry Letters
Widening the SAR around ML221 for apelin receptor antagonists
- Two ML221-derived series were built by varying the arylthio and benzoate regions, giving 32 analogues profiled in an APJ cAMP functional assay.
- Lead Y9 beats ML221 in potency and shifts the Apelin-13 concentration-response curve further to the right, consistent with antagonism.
- In HUVECs, Y9 had low cytotoxicity yet blocked tube formation and DNA synthesis, with G0/G1 arrest.
- In zebrafish it curbed developmental and hypoxia-driven retinal angiogenesis without overt toxicity.
The benzoate ester is the old liability: ML221's ester is a known soft spot for plasma hydrolysis, and Y9's stability is not reported in the abstract, which tempers the zebrafish result. Selectivity against the related AT1 receptor and other GPCRs is likewise absent, and a rightward curve shift alone does not prove competitive binding without Schild-type analysis.
Paper: Bioorganic & Medicinal Chemistry Letters ↗ Structure–activity relationship optimization of ML221-derived non-peptide Apelin receptor antagonists with anti-angiogenic activity